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Objectives. The aim of the study was to compare randomly
assigned primary angioplasty and accelerated recombinant tissue
plasminogen activator (rt-PA), in patients with “high-risk” infe-
rior acute myocardial infarction (ST-segment elevation in the
inferior leads and ST-segment depression in the precordial leads).
Background. The ST-segment depression in the precordial
leads is a marker of severe prognosis in patients with inferior
myocardial infarction. The comparative outcome of treatment
with primary angioplasty or lysis with accelerated rt-PA has not
been investigated.
Methods. One hundred and ten patients within 6 h of symptoms
were randomized to either treatment. To assess the in-hospital
and 1-year outcome of both treatments the following results were
compared: death or nonfatal infarction, recurrence of angina, left
ventricular ejection fraction (LVEF), and the need for repeat
target vessel revascularization (TVR).
Results. In patients treated with angioplasty (55) and rt-PA
(55) the rate of in-hospital mortality and reinfarction was 3.6%
versus 9.1% (p 5 0.4). Recurrence of angina was 1.8% versus 20%
(p 5 0.002), new TVR was used in 3.6% versus 29.1% (p 5 0.0003),
and the LVEF (%) at discharge was 55.2 6 9.5 versus 48.2 6 9.9
(p 5 0.0001). There were no hemorrhagic strokes, no emergency
coronary artery bypass graft (CABG) and identical (5.5%) need
for blood transfusions. At 1 year, the incidence of death, reinfarc-
tion or repeat TVR was 11% in the percutaneous transluminal
coronary angioplasty (PTCA) group versus 52.7% in the rt-PA
group (log-rank 22.38, p < 0.0001).
Conclusions. Primary angioplasty is superior to accelerated
rt-PA in terms of both myocardial preservation and reduction of
in-hospital complications in patients with inferior myocardial
infarction and precordial ST-segment depression. Primary angio-
plasty also yields a better long-term event-free survival.
(J Am Coll Cardiol 1998;32:1687–94)
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Early restoration of a normal blood flow in the infarct-related
artery (IRA) is the mechanism by which reperfusion therapy
improves survival and related clinical outcomes in patients with
acute myocardial infarction (AMI) (1–3). Clinical predictors of
outcome in patients treated with thrombolysis have been
identified in large studies (4). Although there is some evidence
that treatment with percutaneous transluminal coronary angio-
plasty (PTCA) may be more beneficial than thrombolysis,
particularly in higher-risk patients (5,6), the magnitude of both
short- and long-term clinical benefits of PTCA is still inconsis-
tent (7). The accurate identification of subgroups of patients
with AMI who may benefit most from primary PTCA is
important for the rational use of this demanding therapeutic
option.
Inferior AMI is generally considered low-risk, and the
relative benefit of reperfusion therapy may be viewed as
substantially minor (8). However, concomitant precordial
ST-segment depression, as observed in nearly 50% of pa-
tients with inferior AMI (8,9), is a predictor of a more
severe prognosis. In the prethrombolytic era, the mortality
of these patients was reported to be as high as 13% in
hospital, and 11.3% within 1 year (10,11). The benefit of
thrombolytic therapy becomes apparent in these patients
when they are compared to those with ST-segment changes
confined to the inferior leads (8,12). A recent analysis of
data from patients with inferior AMI in the Global Use of
Strategies to Open Occluded Coronary Arteries in Acute
Coronary Syndromes (GUSTO) study has confirmed the
higher rate of complications and mortality associated with
precordial ST-segment depression (13). Although the im-
portance of rapid and aggressive reperfusion therapy in
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these patients is recognized (8,14,15), primary PTCA in this
setting is not currently proposed as a superior treatment.
The aim of this study was to compare both the in-hospital
and long-term results of treatment with either primary PTCA
or thrombolysis using accelerated recombinant tissue plasmin-
ogen activator (rt-PA) in patients with inferior AMI and
concomitant precordial ST-segment depression.
Methods
Study patients. Inclusion criteria. Male and female patients
under the age of 80, presenting within 6 h of symptom onset
(typical chest pain lasting more than 30 min) with ST-segment
elevation .0.1 mV in at least two of the inferior leads, and
concomitant precordial ST-segment depression in at least
three precordial leads, the sum being .3 mm; this criterion
was used to exclude small, low-risk, posterior AMI (15,16).
Informed consent by the patient to participate in the study was
a requisite for inclusion. Exclusion criteria. Formal contraindi-
cations to thrombolysis or to anticoagulation with heparin;
cardiogenic shock or blood pressure ,80 mm Hg (these
patients are selectively treated with primary PTCA), and
anticipated impossibility of percutaneous femoral vascular
access.
Electrocardiographic analysis. The extent of ST-segment
deviation was determined for all leads (measured at 60 ms
after the J point relative to the TP segment). The sums of ST
elevation in the inferior leads (D2-D3,aVF), lateral leads
(V5-V6,D1,aVL), right ventricular leads (V3r,V4r), and of
ST-segment depression in the anterior leads (V1 through V6)
were annotated in all cases.
Randomization and treatment strategies. A brief clinical
history was obtained during physical examination in the Emer-
gency Department. Immediately after informed consent was
obtained, the patients were randomized to one of the two
treatment strategies. The elegibility of the patient for the study
was assessed by the staff cardiologist on duty. Randomization
was performed by means of sealed envelopes. When patients
were allocated to primary PTCA, the emergency team of the
Catheterization Unit was called. All patients received standard
medical care, including aspirin 300 mg IV, ranitidine 50 mg IV,
and nitroglycerin IV when indicated, without lowering systolic
blood pressure ,100 mm Hg; other cardiac medications and
opiates for relief of pain were administered at the discretion of
the physician. Thrombolytic therapy treatment was started in
the Intensive Care Unit; the accelerated, weight-adjusted
treatment with rt-PA was used in all patients randomized to
lytic therapy, according to the GUSTO protocol (17). Heparin
was administered immediately as a 5000-U IV bolus, followed
by an initial infusion of 1000 U/h, which was subsequently
adjusted to maintain the activated partial-thromboplastin time
between two and three times the basal values for 48 h.
Successful thrombolysis was intended as both the relief of
ischemic chest pain and a reduction $50% in ST-segment
elevation after 120 min of the rt-PA bolus. Interruption of
thrombolysis was considered in case of severe hypotension,
bleeding, holosystolic murmur, pulmonary edema, and left
ventricular failure; failed thrombolysis was intended as the
persistence of intense ischemic chest pain or ,50% reduction
in ST-segment elevation at 120 min of the rt-PA bolus; both
these cases were indications for emergency catheterization,
immediately followed by rescue PTCA if the IRA was occluded
and suitable for the procedure.
Primary angioplasty. Patients were transported to the
Catheterization Laboratory as soon as possible for coronary
angiography (the Emergency Department and the Cardiac
Catheterization Laboratory are attached structures, and the
emergency team of the laboratory is on call around the clock).
Immediately after coronary angiography, a bolus of 10,000 U
of heparin was administered IV if PTCA was indicated, and an
activated clotting time .300 s was maintained during the
procedure. A prophylactic bolus of IV lidocaine (1 mg/kg) was
also given before crossing the occlusion with the guide wire.
The PTCA was performed with the conventional technique,
and coronary stents were used without restrictions from the
beginning of the study. Post-PTCA management included
heparin infusion for 48 h prior to sheath removal, and anti-
platelet therapy with ticlopidine 500 mg/day; the latter was
begun immediately after the procedure, and continued for 1
month. The IRA was the only target of the procedure. In the
presence of severe left main coronary artery stenosis, crossover
to intracoronary thrombolysis, followed by urgent coronary
artery bypass graft (CABG) surgery, was indicated only when
the left circumflex was the IRA. In patients with spontaneous
reperfusion of the IRA (TIMI [Thrombolysis in Myocardial
Infarction] grade 3 flow), whether or not to perform the PTCA
was the operator’s choice. Successful PTCA was intended as
TIMI grade 3 coronary flow in the IRA and a residual stenosis
,50%, with relief of ischemic chest pain, and reduction $50%
of ST-segment elevation, as compared to the preprocedure
recording; the lack of any of these features was considered as
failed PTCA, and crossover to intracoronary thrombolysis, with
medical management or urgent CABG, was decided by the
operator. Abciximab was not used in any patient in this study.
Unscheduled catheterization. This procedure was per-
formed in cases of failure of thrombolysis or recurrence of
ischemia. Angiographic analysis. Coronary angiography was
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass graft
CHF 5 congestive heart failure
GUSTO 5 The Global Use of Strategies to Open Occluded
Coronary Arteries in Acute Coronary
Syndromes
IRA 5 infarct-related artery
LVEF 5 left ventricular ejection fraction
PTCA 5 percutaneous transluminal coronary angioplasty
rt-PA 5 recombinant tissue plasminogen activator
TIMI 5 Thrombolysis in Myocardial Infarction
TVR 5 target vessel revascularization
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scheduled in all patients on the day before discharge, but it was
performed at any time earlier if clinically indicated. The TIMI
coronary flow grade and residual stenosis of the IRA, and the
left ventricular ejection fraction (LVEF%) of patients in the
two groups, were compared.
Clinical follow-up. A 6-month control visit was also sched-
uled in all patients. Elective interventions after discharge were
indicated when patients reported symptoms or showed signs of
myocardial ischemia. A telephone follow-up was also obtained
at 12 months for each patient, and a medical examination was
performed in all patients reporting new events.
Study end points. To assess the results of both treatment
strategies, the following variables were compared: A) During
hospital stay: 1A) death (from cardiac and noncardiac origin);
2A) reinfarction defined as chest pain, changes in the ST-T-
segment, and a second increase in the creatine kinase level
to more than twice the upper normal limit, or an increase of
.200 U/l over the previous value if the level had not dropped
to normal; 3A) recurrence of angina at rest with ST-segment
changes; 4A) the need for new target vessel revascularization
(TVR); 5A) nonfatal stroke; 6A) vascular or hemorrhagic
complications needing blood transfusions; 7A) severe ventric-
ular arrhythmia (tachycardia or fibrillation); 8A) congestive
heart failure (CHF, Killip class $2); 9A) the angiographic
result of both treatments at hospital discharge, in terms of
LVEF, IRA patency, and residual stenosis (as assessed by
Quantitative Coronary Analysis with Philips DCI, ACA pack-
age, release 1.1.2); 10A) peak creatine kinase (CK) level and
time to peak; and 11A) the length of initial hospital stay. B)
During the follow-up period the following variables were com-
pared: 1B) death (from cardiac and noncardiac origin); 2B)
reinfarction; 3B) recurrence of angina; 4B) new TVR and
non-TVR; 5B) CHF needing hospital admission; and 6B) total
new hospital admissions.
Statistical analysis. All end points were analyzed accord-
ing to the principle of intention to treat. Continuous data are
expressed as means and standard deviations; discrete variables
are given as absolute values and percentages. The two-tailed
Student’s t test was used for comparison of parametric vari-
ables, and the chi-square test for discrete variables. Event-free
survival analysis was performed using Kaplan-Meier curves
(log-rank test). In case of multiple events (recurrence of
angina, nonfatal reinfarction, death, and new admission for
repeat TVR or CHF) only the first occurring event was
considered.
The research protocol was reviewed and approved by the
ethical board of our institution, and all the patients included in
the study gave their informed consent.
Results
Patient characteristics at recruitment. Between December
1993 and December 1996, a total of 110 consecutive patients
were enrolled and randomized to primary PTCA or thrombol-
ysis; all of the 55 patients in each group received the assigned
protocol treatment. During the study period, 9 additional
patients with inferior AMI and precordial ST-segment depres-
sion were admitted within 6 h of onset, and were not random-
ized: 4 patients presented with systolic blood pressure
,80 mm Hg or with cardiogenic shock, 3 were older than 80
years of age, 1 had contraindication to lysis, and another had
no possibilities of femoral vascular access. The two groups
were similar in terms of baseline characteristics, except for the
heart rate at admission (Table 1). Mean in-hospital delay
(from arrival at the Emergency Department to the beginning
of assigned treatment) was 53.2 6 11.7 min for PTCA and
36.5 6 10.3 min for thrombolysis (p 5 0.0001). In the PTCA
group, reperfusion was achieved within 13.8 min of further
delay; in the rt-PA group the actual time to reperfusion could
not be assessed as early angiography was not performed.
Analysis of the electrocardiographic (ECG) characteristics
shows the similar presentation of patients from the two groups
(Table 2); 64 patients (58.2%) had anterior ST-segment de-
pression from V4 to V6, and 18 (16%) from V1 to V6.
Concomitant right ventricular AMI was present in 35.5% of
our patients.
Procedural and angiographic results. All patients assigned
to the lytic therapy completed the treatment as specified in the
Table 1. Baseline Characteristics of the Two Groups
Characteristics Primary PTCA Group (55) rt-PA Group (55) p Value
Prehospital delay (min) 152.5 6 65.7 (25–355) 154.7 6 69.6 (45–345) 0.9
In-hospital delay (min) 53.2 6 11.7 (25–75) 36.5 6 10.3 (21–90) 0.0001
Gender (males) 45 (82%) 47 (85%) 0.9
Age (years) 63.4 6 8.4 (42–80) 60.2 6 9.6 (36–80) 0.07
Diabetes 9 (16.3%) 6 (10.9%) 0.6
Current smokers 35 (63.6%) 30 (54.5%) 0.7
Hypertension 22 (40%) 25 (45.5%) 0.8
Hypercholesterolemia 20 (36.4%) 24 (43.6%) 0.7
Previous bypass surgery 4 (7.3%) 3 (5.5%) 0.9
Previous PTCA 1 (1.8%) 0 0.9
Previous myocardial infarction 10 (18.2%) 6 (10.9%) 0.5
Heart rate (beats/min) 69.0 6 19.7 76.2 6 16.5 0.04
Systolic blood pressure (mm Hg) 115.8 6 29.9 121.8 6 20.8 0.2
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protocol. Patients in the PTCA group showed an occluded
IRA with TIMI grade 0–1 flow in 49 cases (89%), a TIMI
grade 2 flow in 5 cases (9%), and a spontaneous reperfusion
with TIMI grade 3 flow in 1 case (2%); all were treated with
PTCA. Rescue PTCA of the occluded IRA after failed throm-
bolysis was indicated and was successfully performed in 2
patients. Emergency CABG was not required.
In all patients except one, PTCA was successful (98.2%);
this patient had a TIMI grade 2 coronary flow with persistent
ST elevation at the end of the procedure and was subsequently
managed with medical therapy. Coronary stents were im-
planted in 32 patients (58%). Intraaortic balloon pumping was
used in 5 patients (9%) in the PTCA group, and 2 (3.6%) in the
lytic group. Angiographic data are shown in Table 3.
In-hospital medical management. In addition to heparin,
IV nitrates were given to most patients during the first 48 h.
The subsequent drug regimen used in both groups is listed in
Table 4. The only significant difference was the protocol use of
ticlopidine in patients treated with PTCA, except when specif-
ically contraindicated.
Coronary and left ventricular angiography were performed
before discharge in 51 patients treated with PTCA (92.7%)
and in 52 treated with lytic therapy (94.5%). Angiography was
not performed in 7 patients: this was due to the need for
CABG (3 cases) or to death (2 cases) during hospital stay, to
a local vascular complication during previous primary PTCA (1
case), and to refusal by the patient (1 case). Both the preva-
lence of multivessel disease and the distribution of the IRA
were similar between groups. Coronary TIMI grade flow and
residual stenosis in the IRA and LVEF were significantly
better in the PTCA group than in the trombolysis group (Table
3).
In-hospital clinical outcome. In-hospital events are sum-
marized in Table 5. The differences in mortality and reinfarc-
tion, despite a trend in favor of PTCA, did not reach statistical
significance. In the PTCA group, one patient (1.8%) died after
CABG following successful primary PTCA of a 14-year-old
saphenous vein graft. One patient (1.8%) had reinfarction
attributable to the occlusion of a coil stent; he was promptly
treated with PTCA and had no other complications. One
additional patient needed repeat PTCA for recurrence of
angina at rest (1.8%), and 2 other patients were operated
Table 2. Electrocardiographic Characteristics of the Two Groups
Electrocardiographic Presentation Primary PTCA Group (55) rt-PA Group (55) p Value
S ST elevation in inferior leads
(DII, DIII, aVF) (mm)
18.0 6 5.5 18.0 6 3.9 0.9
S ST elevation in lateral leads
V5, V6, DI, aVL (mm)
15.3 6 4.2 13.7 6 4.2 0.4
Number of cases 6 (11%) 10 (18%) 0.3
S ST depression in precordial leads
(V1 through V6) (mm)
212.2 6 7.6 210.3 6 6.7 0.2
Number of cases 9 (16%) 9 (16%)
S ST depression from V1 to V3 (mm) 26.9 6 4.3 25.8 6 3.9 0.2
Number of cases 15 (27%) 13 (24%) 0.8
S ST depression from V4 to V6 (mm) 25.2 6 4.5 24.2 6 2.3 0.3
Number of cases 31 (57%) 33 (60%) 0.8
S ST elevation in V3-R (mm) 10.65 6 0.9 10.55 6 0.8 0.7
Number of cases 23 (42%) 16 (29%) 0.2
Abbreviations: S: sum.
Table 3. Angiographic Data of the Patient Groups
Angiographic Data Primary PTCA Group (55) rt-PA Group (52) p Value
Infarct related artery
RCA 49 (89%) 42 (81%) 0.2
LCx 6 (11%) 10 (19%) 0.4
One-vessel disease 27 (49%) 26 (50%) 0.8
Two-vessel disease 14 (25.5%) 17 (32.7%) 0.5
Three-vessel disease 14 (25.5%) 9 (17.3%) 0.2
Angiographic findings at discharge
TIMI flow grade
0–1 — 15 (28.8%) 0.0001
2 — 6 (11.6%) 0.01
3 51 (100%) 31 (59.6%) 0.0001
Residual stenosis (%) 20.7 6 13.4 (0–31) 74.6 6 24.7 (4–100) 0.001
Left ventricular ejection fraction (%) 55.2 6 9.5 (35–85) 48.2 6 9.9 (28–68) 0.0001
Abbreviations: Lcx: left circumflex; RCA: right coronary artery.
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before hospital discharge owing to severe left main coronary
artery disease. Three patients from the lytic group (5.5%) died
from recurrent AMI, 2 patients sustained a nonfatal reinfarc-
tion (total reinfarction 9.1%) and 11 had recurrence of angina
at rest. The PTCA was performed successfully in 2 patients as
a rescue procedure for failed thrombolysis, in 1 patient with
reinfarction, in 7 patients with recurrence of angina, in 2
patients with a positive stress test before discharge despite
medical therapy, and in 3 patients electively at discharge due to
preference of the physician. Two patients with unstable symp-
toms had CABG before discharge due to left main coronary
artery disease in one case, and to severe multivessel disease
with post-AMI mitral regurgitation in the other.
Overall, a new TVR was needed in 3.6% of patients of the
PTCA group (2 repeat PTCA), versus 29.1% in the rt-PA
group (15 PTCA and 1 CABG) (p 5 0.0003). A non-TVR was
indicated in 2 patients (3.6%) in the PTCA group, and in 1
patient (1.8%) in the thrombolysis group.
The LVEF% at discharge was significantly better in the
PTCA arm. No patient had intracerebral bleeding, and the
need for blood transfusion was identical in the two groups.
Patients initially treated with thrombolysis had higher (al-
though nonsignificant) peak CK levels, with longer time to
peak. They also had a higher incidence of CHF. The length of
hospital stay was longer in patients initially treated with
thrombolysis (p 5 0.0001).
Follow-up results. No event was observed during the first
month after discharge. During the first semester one patient
randomized to PTCA was readmitted for reinfarction and was
treated medically, and one needed repeat TVR for recurrence
of angina at rest due to in-stent restenosis. In the rt-PA group
one patient died 3 months after CABG, and eight patients
received a new TVR because of recurrence of angina (4 cases),
and to the presence of effort ischemia (4 cases) (p 5 0.01).
Nine additional patients from the rt-PA group received elec-
tive CABG because of multivessel disease and impaired left
ventricular function.
The cumulative incidence of events occurring in the first
year after randomization is shown in Table 6. Figures 1 and 2
show the incidence of death or reinfarction, and of death,
reinfarction or repeat TVR in both groups, as a Kaplan-Meier
1-year event-free survival curve. Recurrence of ischemia (rein-
farction and angina) was observed in 4 patients (7.3%) in the
PTCA group, and in 23 patients (41.8%) in the rt-PA group
(p 5 0.0001). Considering a composite outcome of death,
nonfatal reinfarction, recurrence of angina, and CHF needing
Table 4. Medical Therapy
In-Hospital Medical Therapy Primary PTCA Group (55) rt-PA Group (55) p Value
Aspirin 6 (11%) 42 (72%) 0.0001
Ticlopidine 49 (90%) 13 (24%) 0.0001
Nitrate (oral) 20 (36%) 25 (45%) 0.6
Nitrate (IV) 29 (36%) 14 (25%) 0.4
Beta-blocker (oral) 35 (64%) 37 (67%) 0.9
Agiotensin-converting-enzyme inhibitors 18 (33%) 22 (40%) 0.7
Calcium-channel-blocker 10 (18%) 11 (20%) 0.9
Statin 8 (15%) 7 (13%) 0.9
Table 5. In-Hospital Clinical Outcome
Events Primary PTCA Group (55) rt-PA Group (55) p Value
Death 1 (1.8%) 3 (5.5%) 0.6
Reinfarction (total) 1 (1.8%) 5 (9.1%) (3 fatal) 0.2
Death or nonfatal reinfarction 2 (3.6%) 5 (9.1%) 0.4
Recurrent angina at rest 1 (1.8%) 11 (20%) 0.002
Reinfarction or angina at rest 2 (3.6%) 16 (29.1%) 0.0003
Unscheduled catheterization 2 (3.6%) 14 (25%) 0.01
PTCA in hospital 55 15 (27.3%) —
Bypass surgery in hospital 3 (5.5%) 2 (3.6%) 0.6
Target vessel revascularization 2 (3.6%) 16 (29.1%) 0.0003
Nontarget vessel revascularization 2 (3.6%) 1 (1.8%) 0.5
Stroke 0 0
Bleeding (transfusion needed) 3 (5.5%) 3 (5.5%)
Advanced A-V block 6 (11%) 4 (7.3%) 0.7
Ventricular tachycardia/fibrillation 4 (7.3%) 10 (18%) 0.1
Killip class $2 3 (5.5%) 10 (18%) 0.04
Peak CPK level (ml) 1902 6 1298 (200–4,975) 2432 6 1611 (341–6,890) 0.07
MB fraction 446 6 430 (39–896) 488 6 505 (41–234) 0.6
Time to CPK peak (h) 8.8 6 3.7 (5–24) 12.6 6 4.2 (3–24) 0.0001
Length of hospital stay (days) 9.2 6 2.5 (4–15) 12.4 6 3.7 (6–28) 0.0001
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hospitalization in the first year after randomization, the event-
free survival was 85.5% in the PTCA group (47/55 patients)
versus 54.5% in the thrombolytic group (30/55 patients), odds
ratio 0.32, 95% CI: 0.16 to 0.65; p 5 0.0004.
Discussion
Prior studies have demonstrated that, at selected centers,
primary PTCA in patients with AMI can achieve prompt and
complete reperfusion of the IRA in nearly every case; it also
provides valuable angiographic information whereby the best
therapeutic strategy can be immediately tailored to each
patient. Primary PTCA, however, is a logistically demanding
technique, and IV thrombolysis remains the standard treat-
ment for most patients because of its widespread availability
and its use in a large number of studies in the last decade,
along with proof that it reduces mortality (17–20). Although
data from very recent trials suggest that primary PTCA may
also be more beneficial than thrombolysis in low-risk patients
(7,21), acceptance of primary PTCA as the treatment of choice
for patients with AMI (22) is most likely to be gained through
risk/benefit comparison with thrombolysis in higher-risk pa-
tients, such as those with anterior AMI, older age, heart rate
.100 and cardiogenic shock (5,6,23).
Our study has compared the immediate and long-term
results of primary PTCA and accelerated rt-PA in patients with
inferior AMI and concomitant precordial ST-segment depres-
sion. Only two other randomized studies comparing PTCA
with this thrombolytic regimen have been performed so far
(7,24), and no randomized study is available in this subset of
patients.
The clinical presentation of patients with inferior AMI and
precordial ST-segment depression often fails to meet the
above-mentioned “high-risk” criteria, whereas right ventricular
involvement, advanced atrioventricular block, hemodynami-
cally significant mitral regurgitation, and life-threatening ar-
rhythmias are frequently observed in these patients and por-
tend a severe prognosis (25–29). A recent analysis of results
from the GUSTO-I trial in 16,521 patients with inferior AMI
has confirmed that those with precordial ST-segment depres-
sion have larger infarctions, with a higher rate of complications
Table 6. One-year Follow-up From Admission (110 Patients)
Events Primary PTCA Group (55) rt-PA Group (55) p Value
Time to follow-up (days) 344 6 82 (28–1,213) 329 6 106 (6–1,104) 0.4
Death 2 (3.6%) 4 (7.3%) 0.7
Reinfarction (total) 2 (3.6%) 5 (9.1%) (3 fatal) 0.4
Death or nonfatal reinfarction 4 (7.3%) 6 (11%) 0.7
Recurrence of angina 2 (3.6%) 18 (32.7%) 0.0001
Target vessel revascularization 3 (5.5%) 25 (45.5%) 0.0001
Nontarget vessel revascularization 2 (3.6%) 10 (18%) 0.03
PTCA after randomization 3 (5.5%) 24 (43.6%) 0.0001
Bypass surgery after randomization 3 (5.5%) 11 (20%) 0.05
CHF needing hospitalization 2 (3.6%) 1 (1.8%) 0.5
Hospital readmissions total 4 (7.3%) 21 (38.2) 0.0001
Figure 1. Kaplan-Meier curve of survival and freedom from death or
reinfarction in the study patients, within 365 days after randomization,
according to treatment group. Log rank 0.43, p 5 0.5.
Figure 2. Kaplan-Meier curve of survival and freedom from death,
reinfarction or repeat TVR in the study patients, within 365 days after
randomization, according to treatment group. Log rank 22.38, p 5
0.00001.
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and a higher mortality over both the short and long term; the
magnitude of precordial ST-segment depression is also re-
ported to be an independent prognostic indicator for mortality
at 1 month in these patients (13). Our cohort fits high-risk
criteria for inferior AMI; in fact, patients with a precordial
ST-segment depression ,4 mm limited to leads V1-V3 are
reported to have a better prognosis (13,16) and were not
included; in addition, one-third of our patients had right
ventricular involvement, which is a predictor of failed reper-
fusion by thrombolysis (30) and augmented in-hospital mor-
tality (25,26).
Our study confirms the high immediate success rate of
primary PTCA (5,31–33) also in this group of patients; the
unrestricted use of coronary stents in our cohort may have
contributed to this result (34). In comparison to other random-
ized trials, our results among patients treated with thrombol-
ysis were similar to those obtained with the use of the same
lytic protocol (7). The time necessary to start treatment with
PTCA in our patients was longer than the time needed to begin
thrombolysis, but the additional delay required to reestablish a
normal coronary flow with PTCA was short (5,31,32).
In-hospital mortality and reinfarction. Both mortality and
reinfarction rates in our patients treated with primary PTCA
were lower than in those treated with thrombolysis, although
the differences (1.8 vs. 5.5%, and 1.8 vs. 9.1%, respectively)
were not significant. According to a recent meta-analysis
comparing the results of all randomized trials of primary
PTCA versus thrombolysis, the former has been shown to
reduce the acute mortality by 34% as compared to the latter,
with an estimated gain of about 21 lives saved per 1,000
patients treated (35). Nearly one-third of the mortality differ-
ence favoring PTCA, however, may be due to the higher
incidence of hemorrhagic stroke after thrombolysis (5,21,35).
Intracranial hemorrhage was not observed in our patients.
Early recurrence of ischemia and TVR. In our patients
treated with primary PTCA, recurrent angina at rest during
initial hospital stay was significantly less frequent than in those
treated with thrombolysis (1.8 vs. 20%), as were both unsched-
uled cardiac catheterization (3.6 vs. 25%) and TVR (3.6 vs.
29.1%); as a consequence, the duration of hospital stay was
also significantly shorter (9.2 vs. 12.4 days). This confirms the
results of the primary angioplasty in myocardial infarction
(PAMI) trial substudy in nonanterior AMI (6), with extension
to our special subset of patients; the use of repeat TVR during
hospital stay after initial thrombolysis in our cohort was only
slightly lower than 36%, as reported in that trial (5).
Patency of the IRA and left ventricular function at dis-
charge. As compared to our patients treated with thromboly-
sis, those treated with primary PTCA had both a significantly
higher IRA patency (TIMI grade 3 flow in 100 vs. 59.6%) and
a better preserved left ventricular function; this was reflected
by a higher LVEF (55 vs. 48%) at predischarge coronary
angiography, as well as by a lower incidence of CHF (5.5 vs.
18%). Similarly favorable results after primary PTCA in
comparison to thrombolysis with streptokinase have been
reported by Zijlstra et al. (31) at discharge, and also at 6-month
follow-up in a cohort of nonanterior AMI patients (21). Our
data confirm that primary PTCA yields superior IRA patency
and LVEF preservation at discharge in patients with inferior
AMI and precordial ST-segment depression, and we extend
this observation to comparison with accelerated t-PA.
Long-term follow-up. In the year following randomization,
both the recurrence of angina or reinfarction (7.3%) and the
use of new interventions (11%) among our PTCA patients
were infrequent, although data from this study are difficult to
compare with others (36). The use of coronary stents may have
improved the outcome of PTCA also in the follow-up, when
the advantages of balloon reperfusion over thrombolysis seem
to diminish (7). Myocardial revascularization was often per-
formed in our patients after initial treatment with thrombolysis
(31% before hospital discharge, and 62% within 6 months).
This attitude in our center explains the high rate of new
interventions and hospital readmissions in these patients, and
this may have contributed to their good long-term survival.
Figure 1 shows that differences in event-free survival between
groups were minimal beyond the 6th month. In fact, by that
time 62% of patients initially treated with thrombolysis had
received a revascularization procedure, either complete with
bypass surgery (20%), or limited to the culprit lesion with
PTCA (42%); this “homogenization” of the sample obtained
by the use of invasive procedures after thrombolysis may
account for the fact that, at long term, death and reinfarction
were infrequent in both arms of this trial, as observed in other
studies (37).
Conclusions. Our study shows that primary PTCA with
unrestricted use of stents yields a particularly favorable out-
come, both over the short and long term in patients with
inferior AMI and precordial ST-segment depression, as com-
pared to thrombolysis with accelerated t-PA, in terms of both
myocardial salvage, and recurrent ischemia with subsequent
need for revascularization procedures.
Study limitations. The sample size of this single-center
investigation was limited, and this may be responsible for the
differences observed in the baseline characteristics of patients
in the two patient groups, despite randomization. Our study
was not powered to detect differences in mortality or reinfarc-
tion between the two groups. As a result, the trends observed
in this regard favoring PTCA in this subset of patients require
confirmation by larger studies, with use of both an independent
angiographic core-laboratory, and a committee for the attribu-
tion of events—neither one of which was available for this
single-center trial.
Initial study data were presented at the 45th Meeting of the American College of
Cardiology, February 1996, Orlando, Florida. We are indebted to the staff of
both the Catheterization Laboratory and the Division of Cardiology, which made
this study possible. We wish to thank Dr. Douglas Weaver, from the Cardiovas-
cular Medicine Division of the Henry Ford Heart and Vascular Institute, Detroit,
Michigan, for his valuable suggestions in preparing the manuscript.
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